Reinigen

Volkomen veilig reinigen

  • Sterk reinigend vermogen
  • Makkelijk te gebruiken en in één stuk in zijn geheel te verwijderen
  • Atraumatische verbandwissel
  • Krachtige verticale absorptie

Zuiveren Sepia Reinigen Versnellen Sepia Sluiten Sepia

 

 

 

 

Discover UrgoClean range!

Principe

Het reinigen van een wond kan moeilijk zijn voor clinici (afstervend weefsel pijnloos te verwijderen zonder een bloeding te veroorzaken), maar ook onprettig en pijnlijk voor patiënten (handmatig debridement, bloeding …). Daarom heeft Urgo Medical UrgoClean ontwikkeld, een innovatieve oplossing om exsuderende wonden en wonden met afstervend weefsel op een effectieve en efficiënte manier te reinigen, zodat ze beter kunnen genezen.

 

Werkingsmechanisme

De hydro-reinigende polyacrylaatvezels vormen een gel wanneer ze in contact komen met wondexsudaat. Ze zwellen en binden aan de resten van afstervend weefsel in de wond, die hierdoor geabsorbeerd en afgevoerd worden, wat bijdraagt aan de verwijdering ervan (autolytisch debridement). Deze gelvorming bij contact met de wond zorgt voor een permanent vochtig milieu, dat de genezing van gereinigde gebieden bevordert en exsudaat vasthoudt, zodat dit niet zijwaarts kan diffunderen.

 

VIDEO WERKINGSMECHANISME URGOCLEAN

 

Indicaties

Exsuderende wonden en wonden die afstervend weefsel bevatten (beenulcera, drukulcera, diabetische voetulcera, brandwonden, schaafwonden, traumatische wonden, postoperatieve wonden …)

clean01

 

Contra-indicaties

Waterstofperoxide en antiseptica die hexamidine (Hexomédine®) of organisch kwik bevatten (Mercryl Lauryl®, Dermachrome®, Merfene®).

 

Belangrijkste voordelen

  • Absorbeert afstervend weefsel en bacteriën en voert deze af
  • Kan in één stuk worden verwijderd
  • Zorgt voor atraumatische en pijnloze verbandwisselingen

 

Productlijn

RENIGEN _ RANGE NL

 

Klinisch bewijs

UrgoReviewTC23Feb_Web earth-study-march-2014  
Supporting evidence-based practice: a clinical review of TLC technology Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT)  
Download Download  

 

Management of chronic wounds with an innovative absorbent wound dressing

Meaume S. et al, journal of wound care vol 21 , no 7 , July 2012

  • Objective: To evaluate the efficacy and tolerability of an innovative absorbent wound dressing (UrgoClean; Laboratoires Urgo) in the local management of venous leg ulcers and pressure ulcers, during the sloughy stage of the healing process.
  • Method: A pilot, prospective, non-controlled open-label clinical trial held in 21 investigating centres. Adult patients, presenting with either a venous leg ulcer (VLU ) or a category III /IV pressure ulcer (PU ) with more than 50% of the surface area covered with sloughy tissue, a duration of less than 24 months, and no clinical signs of infection were included in the study. Patients were followed over a 6-week period with weekly visits, which included a physical examination, wound-area tracings and photographs by the investigating physician. Evaluations by the nursing staff and by the patients were made at each dressing change.
  • Results: Fifty patients with either a VLU (n=35) or a PU (n=15) were recruited. At baseline, mean wound surface area was 11.9 ± 11.3 cm2 and 12.5 ± 10.7 cm2, with a mean duration of 8.3 ± 6.4 months and 2.9 ± 3.0 months in the VLU and PU groups, respectively. Wounds in both groups were covered with more than 70% sloughy tissue, and the peri-lesional skin was considered to be healthy in 19 patients. By 6 weeks, mean wound surface area reduction in the VLU and PU groups was 23.7% and 29.2%, respectively, with full healing in 6 patients. All treated wounds were considered to be debrided by week 3 (< 40% slough for all wounds) and the median relative decrease of the sloughy tissue, at week 6, in the VLU and PU groups was 75% and 89%, respectively. Dressing acceptability was documented as being very good for both patients and nursing staff, particularly conformability and ease of use, with no residue left on the wound bed at dressing removal and the dressing also remained in one piece. Seven local adverse events were deemed to be potentially related to the trial dressing.
  • Conclusion: The results suggest that the dressing promoted the healing process of chronic wounds, showing itself to be a credible therapeutic alternative for the sloughy stage of the wound-healing process. It also demonstrated good tolerance and acceptability.
Last update : September 5, 2017